Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine

Modern Rheumatology

Volumn 19, Issue 6, 2009, Pages 681-686

  Nanke, Yuki ^a   Iwatani, Masako ^a   Kobashigawa, Tsuyoshi ^a   Yago, Toru ^a   Yamanaka, Hisashi ^a   Kotake, Shigeru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antirheumatic agents; Bone destruction; Bucillamine; Erosion; Rheumatoid arthritis

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; DICLOFENAC;

ADULT; ANTIGEN ANTIBODY REACTION; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; MALE; PAIN; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOGRAPHY; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BONE AND BONES; CYSTEINE; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73349126701     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0209-6     Document Type: Article

References (24)

1. Y Nanke S Kotake H Akama N Kamatani 2002 Alkaline phosphatase in rheumatoid arthritis patients: possible contribution of bone type ALP to the raised activities of ALP in rheumatoid arthritis patients Clin Rheumatol 21 198 202 10.1007/s10067-002-8285-4 12111623 (Pubitemid 34785006)
2. Y Niino-Nanke H Akama M Hara S Kashiwazaki 1998 Alkaline phosphatase (ALP) activity in rheumatoid arthritis (RA): its clinical significance and synthesis of ALP in RA synovium Riumachi 38 5 12
3. A Suda S Nagaoka S Ohono H Ideguchi T Soga Y Ishigatsubo 2008 The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study Mod Rheumatol 18 609 614 10.1007/s10165-008-0103-7 1:CAS:528:DC%2BD1cXhsVKhtrzK 18682889
4. Y Nanke T Yamada N Kamatani 2005 Asymptomatic interstitial pneumonia induced by bucillamine in a patient with rheumatoid arthritis Mod Rheumatol 15 381 382 10.1007/s10165-005-0417-7 17029099 (Pubitemid 41613979)
5. M Iwatani E Inoue T Nakamura A Nakajima M Hara T Tomatsu, et al. 2006 Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA Mod Rheum 16 376 380 10.1007/s10165-006-0527-x 1:CAS:528:DC%2BD28XhtlSqtbzJ (Pubitemid 44921586)
6. I Yamamoto H Ohmori T Okimura 1982 SA96: an immunopharmacological profile in vitro Int J Tissue React IV 1 1 8
7. K Eguchi A Kawakami H Ida M Nakashima I Yamashita M Sakai, et al. 1992 Bucillamine inhibits T cell adhesion to human endothelial cells J Rheumatol 19 1045 1050 1:CAS:528:DyaK38XlvVCntbs%3D 1512757
8. K Hashimoto PE Lipsky 1993 Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites J Rheumatol 20 953 957 1:CAS:528: DyaK3sXmtFKqtrc%3D 8350330
9. S Hirohata PE Lipsky 1993 Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug Clin Immunol Immunopathol 66 43 51 10.1006/clin.1993.1006 1:CAS:528:DyaK3sXptl2rtQ%3D%3D 8440072 (Pubitemid 23069254)
10. H Aono T Hasunuma K Fujisawa T Nakajima K Yamamoto S Mita, et al. 1995 Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine J Rheumatol 22 65 70
11. Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol. 1998;20:295-304.
12. Shiokawa Y, Ogawa T, Abe T, Kosaka S, Honma M, Akizuki M, et al. Evaluation of drug efficacy of SA96 on rheumatoid arthritis-multicenter double-blinded comparative study. J C E Med. 1985;135(12,13):1116-33.
13. R Rau S Wassenberg G Herborn W Thomas T Perschel G Freitag 2001 Identification of radiologic healing phenomena in patients with rheumatoid arthritis J Rheumatol 12 2608 2615
14. Sharp JT, Heijde D, Boers M, Boonen A, Bruynesteyn K, Emery P, et al. Repair of erosions in rheumatoid arthritis does occur: results from two studies by the OMERACT subcommittee on healing of erosions. J Rheumatol. 2003;30:1102-7.
15. McCarty DJ. Clinical picture of rheumatoid arthritis. In: McCarty DJ, editor. Arthritis and allied conditions. 11th ed. Philadelphia: Lea and Febiger; 1989.
16. H Ideguchi S Ohno H Hattori K Senuma Y Ishigatsubo 2006 Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs Arthrits Res Ther 8 3 R76 10.1186/ar1943
17. St. Clair EW, Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.
18. Klareskon L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. TEMPO (trial of etanercept and methotrexate with radiographic patient outcome) study investigators: therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blinded randomized controlled trial. Lancet. 2004;363:675.
19. Keystone EC, Kavanugh AF, Sharp JT, Tanenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11.
20. N Nishimoto J Hashimoto N Miyasaka K Yamamoto S Kawai T Takeuchi, et al. 2007 Study or active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab Ann Rheum Dis 66 1162 1167 10.1136/ard.2006.068064 1:CAS:528:DC%2BD2sXhtVKltL7O 17485422 (Pubitemid 47309731)
21. S Kotake N Udagawa N Takahashi K Matsuzaki K Itoh S Ishiyama, et al. 1999 IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis J Clin Invest 103 9 1345 1352 10.1172/JCI5703 1:CAS:528:DyaK1MXivFans7c%3D 10225978
22. S Kotake N Udagawa M Hakoda M Mogi K Yano E Tsuda, et al. 2001 Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients Arthritis Rheum 44 5 1003 1012 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0. CO;2-# 1:STN:280:DC%2BD3M3lsVWmsg%3D%3D 11352231 (Pubitemid 32433604)
23. A Suematsu Y Tajiri T Nakashima J Taka S Ochi K Nakamura, et al. 2007 Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis Mod Rheumatol 17 17 23 10.1007/s10165-006-0531-1 1:CAS:528:DC%2BD2sXht1ygur8%3D 17278017 (Pubitemid 46758765)
24. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol. 2004;164:543-55.